文献速递贫血与红细胞疾病

西罗莫司治疗难治/复发性温抗体型自身免疫性溶血性贫血和Evans综合征的前瞻性研究

Sirolimus for refractory/relapsed warm autoimmune hemolytic anemia and Evans syndrome: a prospective study.
PubMed 文献 · Blood Adv · 2026-01-01

该前瞻性单中心开放标签试验纳入78例难治/复发性温抗体型自身免疫性溶血性贫血(wAIHA)或Evans综合征(ES)成人患者,口服西罗莫司(1-3 mg/日,目标谷浓度4-15 ng/mL)至少6个月。6个月总缓解率(ORR)为80.7%,完全缓解率(CRR)为51.3%,12个月ORR和CRR分别为78.2%和50.0%,不良反应多为轻度和可逆。

要点

  • 西罗莫司在R/R wAIHA和ES中6个月ORR达80.7%,CRR达51.3%。
  • 中位起效时间:总体缓解2.4个月,完全缓解3.6个月。
  • 治疗相关不良事件发生率28.2%,以轻度可逆为主。

核心结论

  • 西罗莫司在难治/复发性wAIHA和ES中显示出有临床意义的疗效、持久缓解和良好安全性。

研究设计与样本

  • 前瞻性、单中心、开放标签临床试验,纳入78例R/R wAIHA或ES成人患者,血红蛋白<100 g/L,口服西罗莫司1-3 mg/日(目标谷浓度4-15 ng/mL)至少6个月。

主要发现

  • 6个月ORR为80.7%(wAIHA 81.0%,ES 80.0%),CRR为51.3%(wAIHA 52.4%,ES 46.7%)。
  • 中位随访13.9个月(IQR 12.7-17.0),12个月ORR为78.2%,CRR为50.0%。
  • 中位总体缓解时间2.4个月(IQR 1.8-5.0),完全缓解时间3.6个月(IQR 2.3-7.0)。
  • 治疗相关不良事件发生率28.2%,以轻度可逆为主;复发率12.7%,死亡率2.8%。
  • 基线临床特征与6个月缓解无独立关联。

临床怎么用

  • 西罗莫司可作为激素依赖患者的保激素选项,以及激素难治性R/R wAIHA和ES的潜在治疗替代。

局限性

  • 单中心、开放标签设计可能限制结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Effective therapeutic options remain limited for adults with relapsed or refractory (R/R) warm autoimmune hemolytic anemia (wAIHA) and Evans syndrome (ES). We conducted a prospective, single-center, open-label clinical trial to evaluate the efficacy and safety of sirolimus. Adult patients with R/R wAIHA or ES and hemoglobin levels <100 g/L received oral sirolimus (1-3 mg/day; target trough concentration, 4-15 ng/mL) for ≥6 months. The coprimary end points were overall response rate (ORR) and complete response rate (CRR) at 6 months; secondary end points included 12-month efficacy, safety, and relapse rates. Seventy-eight consecutive patients were enrolled (median age, 52 years [interquartile range (IQR), 38-65]), including 63 (80.8%) with wAIHA and 15 (19.2%) with ES. With a median follow-up of 13.9 months (IQR, 12.7-17.0), sirolimus achieved a 6-month ORR of 80.7% (81.0% for wAIHA and 80.0% for ES) and CRR of 51.3% (52.4% for wAIHA and 46.7% for ES). Median times to overall and complete response were 2.4 months (IQR, 1.8-5.0) and 3.6 months (IQR, 2.3-7.0), respectively. Responses were sustained at 12 months (ORR, 78.2%; CRR, 50.0%). Treatment-emergent adverse events occurred in 28.2% of patients and were predominantly mild and reversible. Relapse and mortality rates were 12.7% and 2.8%, respectively. No baseline clinical characteristics were independently associated with response at 6 months. Sirolimus demonstrated clinically meaningful efficacy, durable responses, and a favorable safety profile, supporting its role as a steroid-sparing option for steroid-dependent patients and a potential treatment alternative for steroid-refractory R/R wAIHA and ES. This trial was registered at www.clinicaltrials.gov as #NCT05925023.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wang Q, Liu Z, Yang C, et al. Sirolimus for refractory/relapsed warm autoimmune hemolytic anemia and Evans syndrome: a prospective study. Blood Adv. 2026. PMID: 42263666. doi:10.1182/bloodadvances.2026019844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。